Efficacy of Vonoprazan with Amoxicillin as the First Line Therapy for Helicobacter pylori Eradication in Asian Population: A Systematic Review, Meta-Analysis, and Meta-Regression of Clinical Studies
Abstract
BACKGROUND AND AIMS: Helicobacter pylori (H. pylori) infection remains a major public health problem in Asia, with high prevalence and increasing therapeutic resistance. Vonoprazan (VPZ), a potassium-competitive acid blocker, combined with amoxicillin is thought to improve eradication rates in first-line therapy. This study evaluated the efficacy of VPZ with amoxicillin as first-line therapy for H. pylori eradication in an Asian population. METHODS: A systematic review and meta-analysis of clinical studies was conducted according to PRISMA guidelines. A literature search was conducted in PubMed and ScienceDirect through September 2025. Data related to the eradication rate (ER) of VPZ-amoxicillin and the comparison of VPZ-amoxicillin eradication with proton pump inhibitors (PPIs) were extracted and analyzed. Data were analyzed using a random-effects model with the main effect sizes being ER and risk difference (RD), as well as meta-regression against age and body mass index (BMI). Data analysis was performed using RevMan 5.4 and R software. RESULTS: This study included 22 clinical studies with 32 comparisons involving 7,498 participants. The VPZ-amoxicillin combination in dual, triple, and quadruple therapy regimens had ERs of 0.92 (95%CI: 0.90-0.95); 0.93 (95%CI: 0.91-0.95); and 0.96 (95%CI: 0.93-0.99), respectively, for a total eradication rate of 0.94 (95%CI: 0.91-0.96). Comparison with PPIs showed a risk difference of 0.06 (95%CI: 0.02-0.09) overall and 0.03 (95%CI:…
How strong is the evidence?
Evidence Hub reads this as a meta-analysis. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid. Reported size: 7,498 participants or records.
Read the paper
Related studies
- The Prediction of the In Vitro Release Curves for PLGA-Based Drug Delivery Systems with Neural Networks
- Promising Ursolic Acid as a Novel Antituberculosis Agent: Current Progress and Challenges
- Proof of principle concept for the analysis and functional prediction of rare genetic variants in the CYP2C19 and CYP2D6 genes
- Fabrication, characterization, and docking studies of furosemide-loaded nanosponges using the emulsion solvent diffusion method
- The Effect of Concomitant Administration of Proton Pump Inhibitors on the Pharmacokinetics of CDK4/6 Inhibitors in Rats: Implications for the Evaluation of Hepatic and Transporter-Mediated Drug–Drug Interactions
- Mining the Metabolic Capacity of Clostridium sporogenes Aided by Machine Learning
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.